On Thursday, Cantor Fitzgerald reiterated its Overweight rating on shares of ORIC Pharmaceuticals (NASDAQ: ORIC), currently trading at $5.97, following the company’s announcement of promising ...

Cantor Fitzgerald analyst Prakhar Agrawal commented on the results, stating, "Overall, a solid update by ORIC with not much to nitpick on efficacy/safety." Agrawal reiterated an Overweight rating on ...

Detailed price information for Oric Pharmaceuticals Inc (ORIC-Q) from The Globe and Mail including charting and trades.

Shares of ORIC Pharmaceuticals Inc. (NASDAQ:ORIC) jumped 20% following the release of early data from its ongoing Phase 1b ...

On Thursday, Cantor Fitzgerald reiterated its Overweight rating on shares of ORIC Pharmaceuticals (NASDAQ: ORIC), currently trading at $5.97, following the company’s announcement of promising Phase 1 ...

Cantor Fitzgerald, a financial services firm, that it entered into a definitive agreement to acquire UBS’s O’Connor ...

U.S. brokerage firm Cantor Fitzgerald has agreed to buy UBS' hedge fund unit, it was announced on Wednesday, expanding Cantor ...

The Cantor Fitzgerald Gold Protected Bitcoin Fund, which the firm said will be its first BTC-focused investment vehicle, is ...